Cervicovaginal dysbiosis as a cofactor of persistent human papillomavirus infection and progression of cervical neoplasia
Partner conferences of the International Scientific Journal Research Focus · 30.10.2026 · 1 (8) · 434-436
DOI: 10.66073/refocus-conf/3010122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Partner conferences of the International Scientific Journal Research Focus, online erschienen am 30.10.2026. Verfasst von Abdullayeva Madinakhon Isokjon kizi. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Studies published in 2011–2025 on the role of cervicovaginal dysbiosis in the persistence of high-risk human papillomavirus (HPV) and the progression of cervical intraepithelial neoplasia (CIN) were analysed. The Lactobacillus-depleted community state CST IV, dominated by anaerobic bacteria, increases the odds of HPV detection, and its share rises from 10% in normal cytology to 40% in invasive cancer. Assessment of the microbiocenosis in HPV-positive women may improve risk stratification.
Zitieren
APA
kizi, A. M. I. (2026). Cervicovaginal dysbiosis as a cofactor of persistent human papillomavirus infection and progression of cervical neoplasia. Partner conferences of the International Scientific Journal Research Focus, 1(8), 434-436. https://doi.org/10.66073/refocus-conf/3010122
Vancouver
kizi AMI. Cervicovaginal dysbiosis as a cofactor of persistent human papillomavirus infection and progression of cervical neoplasia. Partner conferences of the International Scientific Journal Research Focus. 2026;1(8):434-436. doi:10.66073/refocus-conf/3010122
BibTeX
@article{kizi2026,
author = {kizi, Abdullayeva Madinakhon Isokjon},
title = {Cervicovaginal dysbiosis as a cofactor of persistent human papillomavirus infection and progression of cervical neoplasia},
journal = {Partner conferences of the International Scientific Journal Research Focus},
year = {2026},
volume = {1},
number = {8},
pages = {434--436},
doi = {10.66073/refocus-conf/3010122}
}
EUVIMED